Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)
Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes to immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of in the response to avelumab in advanced urothelial cancer (aUC). Thus, we reported outcomes by NER of aUC patients...
Gespeichert in:
| Veröffentlicht in: | Clinical genitourinary cancer 2024-08, Vol.22 (4), p.102099, Article 102099 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 102099 |
| container_title | Clinical genitourinary cancer |
| container_volume | 22 |
| creator | Gambale, Elisabetta Maruzzo, Marco Messina, Carlo De Gennaro Aquino, Irene Vascotto, Ismaela Anna Rossi, Virginia Bimbatti, Davide Cavasin, Nicolò Messina, Marco Mennitto, Alessia Rebuzzi, Sara Elena Nasso, Cecilia Mercinelli, Chiara Maiorano, Brigida Anna Fanelli, Martina Sorarù, Mariella Scolari, Federico Mela, Marinella Micol Galli, Luca Salfi, Alessia Rizzo, Mimma Puglisi, Silvia Orlando, Valentina Fornarini, Giuseppe Rametta, Alessandro Giannatempo, Patrizia Cerbone, Linda Doni, Laura Roviello, Giandomenico Pillozzi, Serena Antonuzzo, Lorenzo |
| description | Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes to immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of in the response to avelumab in advanced urothelial cancer (aUC). Thus, we reported outcomes by NER of aUC patients treated with avelumab as maintenance after initial response to platinum-based chemotherapy and enrolled in the Maintenance with AVeLumAb ([MALVA] in advanced urothelial neoplasms in response to first-line chemotherapy: an observational retrospective study) study (Meet-URO 25).
Median NER at baseline and after 3 cycles of avelumab were calculated. Progression-free survival (PFS) and overall survival (OS) by NER were reported.
At the cutoff date (April 15, 2023), a total of 109 patients were included. The median NER was 28.05 at baseline and 24.46 after 3 cycles of avelumab, respectively. Median PFS was not reached for patients with baseline NER less than the median ( |
| doi_str_mv | 10.1016/j.clgc.2024.102099 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3059259322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1558767324000703</els_id><sourcerecordid>3059259322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-7d98e7d3d00e263d45aa1b1a98d1772a868b7a8e2d59131ef4df56a47ac0c36b3</originalsourceid><addsrcrecordid>eNp9kcuO0zAUhiMEYoaBF2CBvBwWKb7EcSKxiapykTrMaKCwtBz7hLpy4o7tVOqj8La4dGDJyrfv_yWfryheE7wgmNTvdgvtfuoFxbTKFxS37ZPikrSsKXHd0Kd5z3lTilqwi-JFjDuMK04Efl5csEaImjfssvj1BeYU_H5rXZl8ufLRTn9O6F4l69FdAGN1iihtAa2GwWqlj8gPqDuAm0fVIzuhu4zClKEfNm1RZw5q0mDQJvicclY5tFRB5-JRodUUvHP5NedOnTfd-nuHvqbZHNH1DUAqN_e3iPK3L4tng3IRXj2uV8Xmw-rb8lO5vv34edmtS804SaUwbQPCMIMx0JqZiitFeqLaxhAhqGrqpheqAWp4SxiBoTIDr1UllMaa1T27Kq7PvfvgH2aISY42anBOTeDnKBnmLeUtozSj9Izq4GMMMMh9sKMKR0mwPCmRO3lSIk9K5FlJDr157J_7Ecy_yF8HGXh_BiD_8mAhyKjzOPMEbQCdpPH2f_2_AZpJnQ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3059259322</pqid></control><display><type>article</type><title>Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Gambale, Elisabetta ; Maruzzo, Marco ; Messina, Carlo ; De Gennaro Aquino, Irene ; Vascotto, Ismaela Anna ; Rossi, Virginia ; Bimbatti, Davide ; Cavasin, Nicolò ; Messina, Marco ; Mennitto, Alessia ; Rebuzzi, Sara Elena ; Nasso, Cecilia ; Mercinelli, Chiara ; Maiorano, Brigida Anna ; Fanelli, Martina ; Sorarù, Mariella ; Scolari, Federico ; Mela, Marinella Micol ; Galli, Luca ; Salfi, Alessia ; Rizzo, Mimma ; Puglisi, Silvia ; Orlando, Valentina ; Fornarini, Giuseppe ; Rametta, Alessandro ; Giannatempo, Patrizia ; Cerbone, Linda ; Doni, Laura ; Roviello, Giandomenico ; Pillozzi, Serena ; Antonuzzo, Lorenzo</creator><creatorcontrib>Gambale, Elisabetta ; Maruzzo, Marco ; Messina, Carlo ; De Gennaro Aquino, Irene ; Vascotto, Ismaela Anna ; Rossi, Virginia ; Bimbatti, Davide ; Cavasin, Nicolò ; Messina, Marco ; Mennitto, Alessia ; Rebuzzi, Sara Elena ; Nasso, Cecilia ; Mercinelli, Chiara ; Maiorano, Brigida Anna ; Fanelli, Martina ; Sorarù, Mariella ; Scolari, Federico ; Mela, Marinella Micol ; Galli, Luca ; Salfi, Alessia ; Rizzo, Mimma ; Puglisi, Silvia ; Orlando, Valentina ; Fornarini, Giuseppe ; Rametta, Alessandro ; Giannatempo, Patrizia ; Cerbone, Linda ; Doni, Laura ; Roviello, Giandomenico ; Pillozzi, Serena ; Antonuzzo, Lorenzo</creatorcontrib><description>Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes to immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of in the response to avelumab in advanced urothelial cancer (aUC). Thus, we reported outcomes by NER of aUC patients treated with avelumab as maintenance after initial response to platinum-based chemotherapy and enrolled in the Maintenance with AVeLumAb ([MALVA] in advanced urothelial neoplasms in response to first-line chemotherapy: an observational retrospective study) study (Meet-URO 25).
Median NER at baseline and after 3 cycles of avelumab were calculated. Progression-free survival (PFS) and overall survival (OS) by NER were reported.
At the cutoff date (April 15, 2023), a total of 109 patients were included. The median NER was 28.05 at baseline and 24.46 after 3 cycles of avelumab, respectively. Median PFS was not reached for patients with baseline NER less than the median (<median) compared to 5.1 months for patients with baseline NER greater than the median (≥median) (P = .0005). Median OS was significantly longer for patients with baseline NER <median compared with patients with baseline NER ≥median (not reached vs. 11.7 months, respectively; P = .0016). Significantly better PFS and OS were confirmed for NER after 3 cycles of avelumab <median compared with NER ≥median at the same timepoint.
NER <median may be predictive of PFS in aUC patients treated with avelumab, and prognostic for OS regardless of treatment. Prospective studies are warranted to validate NER as a readily available and reproducible laboratory-biomarker for efficacy outcomes of avelumab in aUC.
Our retrospective analysis from MALVA Meet-URO 25 study reports progression-free survival (PFS) and overall survival (OS) by neutrophil-to-eosinophil ratio (NER) during avelumab treatment for advanced urothelial cancer (aUC). NER <median may be predictive of PFS, and prognostic for OS regardless of treatment. Prospective studies are warranted to validate NER as reproducible laboratory-biomarker for efficacy outcomes of avelumab in aUC.</description><identifier>ISSN: 1558-7673</identifier><identifier>ISSN: 1938-0682</identifier><identifier>EISSN: 1938-0682</identifier><identifier>DOI: 10.1016/j.clgc.2024.102099</identifier><identifier>PMID: 38776583</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents, Immunological - therapeutic use ; Biomarker ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - pathology ; Eosinophilia ; Female ; Humans ; Male ; Middle Aged ; Neutrophils ; Predictive factors ; Prognosis ; Prognostic factors ; Progression-Free Survival ; Retrospective Studies ; Treatment Outcome ; Urologic Neoplasms - drug therapy ; Urologic Neoplasms - pathology</subject><ispartof>Clinical genitourinary cancer, 2024-08, Vol.22 (4), p.102099, Article 102099</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c351t-7d98e7d3d00e263d45aa1b1a98d1772a868b7a8e2d59131ef4df56a47ac0c36b3</cites><orcidid>0000-0002-7934-1419 ; 0000-0001-5490-672X ; 0000-0003-0546-6304 ; 0000-0001-6008-0266 ; 0000-0001-5423-3158 ; 0000-0002-3665-3295 ; 0000-0002-6256-9249 ; 0000-0001-5198-7755 ; 0000-0003-1165-1776 ; 0000-0001-9755-0567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38776583$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gambale, Elisabetta</creatorcontrib><creatorcontrib>Maruzzo, Marco</creatorcontrib><creatorcontrib>Messina, Carlo</creatorcontrib><creatorcontrib>De Gennaro Aquino, Irene</creatorcontrib><creatorcontrib>Vascotto, Ismaela Anna</creatorcontrib><creatorcontrib>Rossi, Virginia</creatorcontrib><creatorcontrib>Bimbatti, Davide</creatorcontrib><creatorcontrib>Cavasin, Nicolò</creatorcontrib><creatorcontrib>Messina, Marco</creatorcontrib><creatorcontrib>Mennitto, Alessia</creatorcontrib><creatorcontrib>Rebuzzi, Sara Elena</creatorcontrib><creatorcontrib>Nasso, Cecilia</creatorcontrib><creatorcontrib>Mercinelli, Chiara</creatorcontrib><creatorcontrib>Maiorano, Brigida Anna</creatorcontrib><creatorcontrib>Fanelli, Martina</creatorcontrib><creatorcontrib>Sorarù, Mariella</creatorcontrib><creatorcontrib>Scolari, Federico</creatorcontrib><creatorcontrib>Mela, Marinella Micol</creatorcontrib><creatorcontrib>Galli, Luca</creatorcontrib><creatorcontrib>Salfi, Alessia</creatorcontrib><creatorcontrib>Rizzo, Mimma</creatorcontrib><creatorcontrib>Puglisi, Silvia</creatorcontrib><creatorcontrib>Orlando, Valentina</creatorcontrib><creatorcontrib>Fornarini, Giuseppe</creatorcontrib><creatorcontrib>Rametta, Alessandro</creatorcontrib><creatorcontrib>Giannatempo, Patrizia</creatorcontrib><creatorcontrib>Cerbone, Linda</creatorcontrib><creatorcontrib>Doni, Laura</creatorcontrib><creatorcontrib>Roviello, Giandomenico</creatorcontrib><creatorcontrib>Pillozzi, Serena</creatorcontrib><creatorcontrib>Antonuzzo, Lorenzo</creatorcontrib><title>Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)</title><title>Clinical genitourinary cancer</title><addtitle>Clin Genitourin Cancer</addtitle><description>Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes to immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of in the response to avelumab in advanced urothelial cancer (aUC). Thus, we reported outcomes by NER of aUC patients treated with avelumab as maintenance after initial response to platinum-based chemotherapy and enrolled in the Maintenance with AVeLumAb ([MALVA] in advanced urothelial neoplasms in response to first-line chemotherapy: an observational retrospective study) study (Meet-URO 25).
Median NER at baseline and after 3 cycles of avelumab were calculated. Progression-free survival (PFS) and overall survival (OS) by NER were reported.
At the cutoff date (April 15, 2023), a total of 109 patients were included. The median NER was 28.05 at baseline and 24.46 after 3 cycles of avelumab, respectively. Median PFS was not reached for patients with baseline NER less than the median (<median) compared to 5.1 months for patients with baseline NER greater than the median (≥median) (P = .0005). Median OS was significantly longer for patients with baseline NER <median compared with patients with baseline NER ≥median (not reached vs. 11.7 months, respectively; P = .0016). Significantly better PFS and OS were confirmed for NER after 3 cycles of avelumab <median compared with NER ≥median at the same timepoint.
NER <median may be predictive of PFS in aUC patients treated with avelumab, and prognostic for OS regardless of treatment. Prospective studies are warranted to validate NER as a readily available and reproducible laboratory-biomarker for efficacy outcomes of avelumab in aUC.
Our retrospective analysis from MALVA Meet-URO 25 study reports progression-free survival (PFS) and overall survival (OS) by neutrophil-to-eosinophil ratio (NER) during avelumab treatment for advanced urothelial cancer (aUC). NER <median may be predictive of PFS, and prognostic for OS regardless of treatment. Prospective studies are warranted to validate NER as reproducible laboratory-biomarker for efficacy outcomes of avelumab in aUC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Biomarker</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Eosinophilia</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neutrophils</subject><subject>Predictive factors</subject><subject>Prognosis</subject><subject>Prognostic factors</subject><subject>Progression-Free Survival</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Urologic Neoplasms - drug therapy</subject><subject>Urologic Neoplasms - pathology</subject><issn>1558-7673</issn><issn>1938-0682</issn><issn>1938-0682</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcuO0zAUhiMEYoaBF2CBvBwWKb7EcSKxiapykTrMaKCwtBz7hLpy4o7tVOqj8La4dGDJyrfv_yWfryheE7wgmNTvdgvtfuoFxbTKFxS37ZPikrSsKXHd0Kd5z3lTilqwi-JFjDuMK04Efl5csEaImjfssvj1BeYU_H5rXZl8ufLRTn9O6F4l69FdAGN1iihtAa2GwWqlj8gPqDuAm0fVIzuhu4zClKEfNm1RZw5q0mDQJvicclY5tFRB5-JRodUUvHP5NedOnTfd-nuHvqbZHNH1DUAqN_e3iPK3L4tng3IRXj2uV8Xmw-rb8lO5vv34edmtS804SaUwbQPCMIMx0JqZiitFeqLaxhAhqGrqpheqAWp4SxiBoTIDr1UllMaa1T27Kq7PvfvgH2aISY42anBOTeDnKBnmLeUtozSj9Izq4GMMMMh9sKMKR0mwPCmRO3lSIk9K5FlJDr157J_7Ecy_yF8HGXh_BiD_8mAhyKjzOPMEbQCdpPH2f_2_AZpJnQ0</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Gambale, Elisabetta</creator><creator>Maruzzo, Marco</creator><creator>Messina, Carlo</creator><creator>De Gennaro Aquino, Irene</creator><creator>Vascotto, Ismaela Anna</creator><creator>Rossi, Virginia</creator><creator>Bimbatti, Davide</creator><creator>Cavasin, Nicolò</creator><creator>Messina, Marco</creator><creator>Mennitto, Alessia</creator><creator>Rebuzzi, Sara Elena</creator><creator>Nasso, Cecilia</creator><creator>Mercinelli, Chiara</creator><creator>Maiorano, Brigida Anna</creator><creator>Fanelli, Martina</creator><creator>Sorarù, Mariella</creator><creator>Scolari, Federico</creator><creator>Mela, Marinella Micol</creator><creator>Galli, Luca</creator><creator>Salfi, Alessia</creator><creator>Rizzo, Mimma</creator><creator>Puglisi, Silvia</creator><creator>Orlando, Valentina</creator><creator>Fornarini, Giuseppe</creator><creator>Rametta, Alessandro</creator><creator>Giannatempo, Patrizia</creator><creator>Cerbone, Linda</creator><creator>Doni, Laura</creator><creator>Roviello, Giandomenico</creator><creator>Pillozzi, Serena</creator><creator>Antonuzzo, Lorenzo</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7934-1419</orcidid><orcidid>https://orcid.org/0000-0001-5490-672X</orcidid><orcidid>https://orcid.org/0000-0003-0546-6304</orcidid><orcidid>https://orcid.org/0000-0001-6008-0266</orcidid><orcidid>https://orcid.org/0000-0001-5423-3158</orcidid><orcidid>https://orcid.org/0000-0002-3665-3295</orcidid><orcidid>https://orcid.org/0000-0002-6256-9249</orcidid><orcidid>https://orcid.org/0000-0001-5198-7755</orcidid><orcidid>https://orcid.org/0000-0003-1165-1776</orcidid><orcidid>https://orcid.org/0000-0001-9755-0567</orcidid></search><sort><creationdate>202408</creationdate><title>Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)</title><author>Gambale, Elisabetta ; Maruzzo, Marco ; Messina, Carlo ; De Gennaro Aquino, Irene ; Vascotto, Ismaela Anna ; Rossi, Virginia ; Bimbatti, Davide ; Cavasin, Nicolò ; Messina, Marco ; Mennitto, Alessia ; Rebuzzi, Sara Elena ; Nasso, Cecilia ; Mercinelli, Chiara ; Maiorano, Brigida Anna ; Fanelli, Martina ; Sorarù, Mariella ; Scolari, Federico ; Mela, Marinella Micol ; Galli, Luca ; Salfi, Alessia ; Rizzo, Mimma ; Puglisi, Silvia ; Orlando, Valentina ; Fornarini, Giuseppe ; Rametta, Alessandro ; Giannatempo, Patrizia ; Cerbone, Linda ; Doni, Laura ; Roviello, Giandomenico ; Pillozzi, Serena ; Antonuzzo, Lorenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-7d98e7d3d00e263d45aa1b1a98d1772a868b7a8e2d59131ef4df56a47ac0c36b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Biomarker</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Eosinophilia</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neutrophils</topic><topic>Predictive factors</topic><topic>Prognosis</topic><topic>Prognostic factors</topic><topic>Progression-Free Survival</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Urologic Neoplasms - drug therapy</topic><topic>Urologic Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gambale, Elisabetta</creatorcontrib><creatorcontrib>Maruzzo, Marco</creatorcontrib><creatorcontrib>Messina, Carlo</creatorcontrib><creatorcontrib>De Gennaro Aquino, Irene</creatorcontrib><creatorcontrib>Vascotto, Ismaela Anna</creatorcontrib><creatorcontrib>Rossi, Virginia</creatorcontrib><creatorcontrib>Bimbatti, Davide</creatorcontrib><creatorcontrib>Cavasin, Nicolò</creatorcontrib><creatorcontrib>Messina, Marco</creatorcontrib><creatorcontrib>Mennitto, Alessia</creatorcontrib><creatorcontrib>Rebuzzi, Sara Elena</creatorcontrib><creatorcontrib>Nasso, Cecilia</creatorcontrib><creatorcontrib>Mercinelli, Chiara</creatorcontrib><creatorcontrib>Maiorano, Brigida Anna</creatorcontrib><creatorcontrib>Fanelli, Martina</creatorcontrib><creatorcontrib>Sorarù, Mariella</creatorcontrib><creatorcontrib>Scolari, Federico</creatorcontrib><creatorcontrib>Mela, Marinella Micol</creatorcontrib><creatorcontrib>Galli, Luca</creatorcontrib><creatorcontrib>Salfi, Alessia</creatorcontrib><creatorcontrib>Rizzo, Mimma</creatorcontrib><creatorcontrib>Puglisi, Silvia</creatorcontrib><creatorcontrib>Orlando, Valentina</creatorcontrib><creatorcontrib>Fornarini, Giuseppe</creatorcontrib><creatorcontrib>Rametta, Alessandro</creatorcontrib><creatorcontrib>Giannatempo, Patrizia</creatorcontrib><creatorcontrib>Cerbone, Linda</creatorcontrib><creatorcontrib>Doni, Laura</creatorcontrib><creatorcontrib>Roviello, Giandomenico</creatorcontrib><creatorcontrib>Pillozzi, Serena</creatorcontrib><creatorcontrib>Antonuzzo, Lorenzo</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genitourinary cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gambale, Elisabetta</au><au>Maruzzo, Marco</au><au>Messina, Carlo</au><au>De Gennaro Aquino, Irene</au><au>Vascotto, Ismaela Anna</au><au>Rossi, Virginia</au><au>Bimbatti, Davide</au><au>Cavasin, Nicolò</au><au>Messina, Marco</au><au>Mennitto, Alessia</au><au>Rebuzzi, Sara Elena</au><au>Nasso, Cecilia</au><au>Mercinelli, Chiara</au><au>Maiorano, Brigida Anna</au><au>Fanelli, Martina</au><au>Sorarù, Mariella</au><au>Scolari, Federico</au><au>Mela, Marinella Micol</au><au>Galli, Luca</au><au>Salfi, Alessia</au><au>Rizzo, Mimma</au><au>Puglisi, Silvia</au><au>Orlando, Valentina</au><au>Fornarini, Giuseppe</au><au>Rametta, Alessandro</au><au>Giannatempo, Patrizia</au><au>Cerbone, Linda</au><au>Doni, Laura</au><au>Roviello, Giandomenico</au><au>Pillozzi, Serena</au><au>Antonuzzo, Lorenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)</atitle><jtitle>Clinical genitourinary cancer</jtitle><addtitle>Clin Genitourin Cancer</addtitle><date>2024-08</date><risdate>2024</risdate><volume>22</volume><issue>4</issue><spage>102099</spage><pages>102099-</pages><artnum>102099</artnum><issn>1558-7673</issn><issn>1938-0682</issn><eissn>1938-0682</eissn><abstract>Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes to immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of in the response to avelumab in advanced urothelial cancer (aUC). Thus, we reported outcomes by NER of aUC patients treated with avelumab as maintenance after initial response to platinum-based chemotherapy and enrolled in the Maintenance with AVeLumAb ([MALVA] in advanced urothelial neoplasms in response to first-line chemotherapy: an observational retrospective study) study (Meet-URO 25).
Median NER at baseline and after 3 cycles of avelumab were calculated. Progression-free survival (PFS) and overall survival (OS) by NER were reported.
At the cutoff date (April 15, 2023), a total of 109 patients were included. The median NER was 28.05 at baseline and 24.46 after 3 cycles of avelumab, respectively. Median PFS was not reached for patients with baseline NER less than the median (<median) compared to 5.1 months for patients with baseline NER greater than the median (≥median) (P = .0005). Median OS was significantly longer for patients with baseline NER <median compared with patients with baseline NER ≥median (not reached vs. 11.7 months, respectively; P = .0016). Significantly better PFS and OS were confirmed for NER after 3 cycles of avelumab <median compared with NER ≥median at the same timepoint.
NER <median may be predictive of PFS in aUC patients treated with avelumab, and prognostic for OS regardless of treatment. Prospective studies are warranted to validate NER as a readily available and reproducible laboratory-biomarker for efficacy outcomes of avelumab in aUC.
Our retrospective analysis from MALVA Meet-URO 25 study reports progression-free survival (PFS) and overall survival (OS) by neutrophil-to-eosinophil ratio (NER) during avelumab treatment for advanced urothelial cancer (aUC). NER <median may be predictive of PFS, and prognostic for OS regardless of treatment. Prospective studies are warranted to validate NER as reproducible laboratory-biomarker for efficacy outcomes of avelumab in aUC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38776583</pmid><doi>10.1016/j.clgc.2024.102099</doi><orcidid>https://orcid.org/0000-0002-7934-1419</orcidid><orcidid>https://orcid.org/0000-0001-5490-672X</orcidid><orcidid>https://orcid.org/0000-0003-0546-6304</orcidid><orcidid>https://orcid.org/0000-0001-6008-0266</orcidid><orcidid>https://orcid.org/0000-0001-5423-3158</orcidid><orcidid>https://orcid.org/0000-0002-3665-3295</orcidid><orcidid>https://orcid.org/0000-0002-6256-9249</orcidid><orcidid>https://orcid.org/0000-0001-5198-7755</orcidid><orcidid>https://orcid.org/0000-0003-1165-1776</orcidid><orcidid>https://orcid.org/0000-0001-9755-0567</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1558-7673 |
| ispartof | Clinical genitourinary cancer, 2024-08, Vol.22 (4), p.102099, Article 102099 |
| issn | 1558-7673 1938-0682 1938-0682 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3059259322 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarker Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Eosinophilia Female Humans Male Middle Aged Neutrophils Predictive factors Prognosis Prognostic factors Progression-Free Survival Retrospective Studies Treatment Outcome Urologic Neoplasms - drug therapy Urologic Neoplasms - pathology |
| title | Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A52%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil-to-Eosinophil%20Ratio%20Predicts%20the%20Efficacy%20of%20Avelumab%20in%20Patients%20With%20Advanced%20Urothelial%20Carcinoma%20Enrolled%20in%20the%20MALVA%20Study%20(Meet-URO%2025)&rft.jtitle=Clinical%20genitourinary%20cancer&rft.au=Gambale,%20Elisabetta&rft.date=2024-08&rft.volume=22&rft.issue=4&rft.spage=102099&rft.pages=102099-&rft.artnum=102099&rft.issn=1558-7673&rft.eissn=1938-0682&rft_id=info:doi/10.1016/j.clgc.2024.102099&rft_dat=%3Cproquest_cross%3E3059259322%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3059259322&rft_id=info:pmid/38776583&rft_els_id=S1558767324000703&rfr_iscdi=true |